Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Prime Medicine, Inc.

NASDAQ: PRME · Life Sciences · 4 alerts · CIK 1894562

Share price
$4.19Close, Nov 16
Market cap
$762M
Shares outstanding
181.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Prime Medicine, Inc. filings on SEC EDGAR ↗

4:12 PM ET 10-Q
Financial Results

Prime Medicine Q3 2026 Results: Net Loss of $39M, Loss Narrows

Prime Medicine reported a net loss of $130.3 million for the nine months ended September 30, 2026, an improvement from the $155.1 million loss in the prior year period. Total revenue increased to $6.2 million, primarily driven by collaboration revenue from related parties, while total stockholders' equity significantly declined from $120.9 million to $8.4 million during the first nine months of 2026.

Key figure
Net loss $39M
4:07 PM ET 8-K
Financial Results

Prime Medicine Financial Results

Prime Medicine reported Q3 2026 financial results, highlighting the first patient dosed in its Phase 1/2 trial for Wilson disease and FDA clearance for its AATD program. The company also completed a $143.7 million public offering, extending its cash runway through 2027.

Term
Q3 2026

“Prime Medicine continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for Wilson disease, our first clinical study of an in vivo Prime Editing therapy.”

Allan Reine, M.D., Chief Executive Officer

“Our recent financing strengthens our balance sheet and provides additional resources needed to advance these programs through key clinical milestones. Looking ahead, we expect 2027 to be a meaningful year for the patient communities we hope to treat, with initial clinical data anticipated from both PM577a and PM647 and a planned BLA submission for PM359.”

Allan Reine, M.D., Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.